Meningococcal disease by infectious bacteria in Ecuador
Keywords:
symptomatologies, meningococcal disease, meningitisAbstract
Introduction: meningitis can affect at any age and healthy individuals; it´s the inflammation of the meninges caused by the infection with pyogenic bacteria. Meningococcal disease is prevalent worldwide and constitutes a medical emergency with high morbidity and mortality.
Objective: to assess the symptomatology of meningococcal disease in Ecuador.
Method: a qualitative-quantitative research was carried out, an exhaustive bibliographic review was conducted in bibliographic search engines with the use of keywords: meningococcal disease caused by infectious bacteria. A total of 151 affected patients (as universe) were studied. The variables: age of those affected patients, dependent risk factors and symptoms present, helped in the authors final conclusions.
Results: the 56.30% of the studied population was male, with an average age of approximately 10 months. The 63.58% of the studied population is under 1 year of age, the number of symptoms presented was variable, 11% with 4 or more symptoms and 47% with one symptom. Poor hygiene was presented in 35.20%. Symptomatology is related to the consumption of snails and unboiled water.
Conclusions: meningococcal disease causes damage to the brain and spinal cord, and infections has increased in recent years. Inadequate food sanitation is one of the risks for acquiring the disease. The most frequent symptoms are: neurological involvement, convulsions, vomiting and nausea, as well as the presence of eosinophils in blood and cerebrospinal fluid.
Downloads
References
2. Mafla MAG, Murillo HPV, Castellanos DGS, Martínez SER. Agentes etiológicos más frecuentes de neuro infección en pacientes pediátricos. RECIAMUC [Internet]. 2021 [citado 27 Oct 2022]; 5(3):4-12. Disponible en: https://reciamuc.com/index.php/RECIAMUC/article/view/680
3. Davis LE. Acute Bacterial Meningitis. Continuum (Minneap Minn) [Internet]. Oct 2018 [citado 27 Oct 2022]; 24(5):1264-83. Disponible en: https://pubmed.ncbi.nlm.nih.gov/30273239/
4. Jimbo Sotomayor RE. Consideraciones epidemiológicas de la enfermedad neumocócica e impacto clínico y económico de la vacuna antineumocócica (PCV-10) en niños menores de 5 años en el Ecuador [tesis doctoral]. Ecuador: Universidad de Alcalá; 2021. [citado 27 Oct 2022]; Disponible en: https://ebuah.uah.es/dspace/handle/10017/50948
5. Parreño KSB, García AAG, Parra PDP, Jumbo KEH. Meningitis bacteriana en paciente pediátrico. RECIMUNDO [Internet]. 2021 [citado 27 Oct 2022]; 5(4):45-52. DOI: https://doi.org/10.26820/recimundo/5.(4).oct.2021.45-52
6. Sánchez-Gómez JE, Avellan-Lara LF, Veloz-Estrada LS, Pluas-Alvario AE. Meningitis bacteriana cuadro clínico, causas, complicaciones y tratamiento. Dominio de las Ciencias [Internet]. 2021 [citado 27 Oct 2022]; 7(6):1386-405. Disponible en: https://dominiodelasciencias.com/ojs/index.php/es/article/view/2400
7. Campillo NE, Cañelles López M, Jiménez Sarmiento M. Las vacunas [Internet]. España: Los libros de la catarata; 2022. [citado 28 Oct 2022]. Disponible en: https://www.agapea.com/libros/Las-vacunas-Ebook--EB9788413524382-i.htm
8. Soneira MS, Alférez MDRC, Portero RC. Enfermedad meningocócica. Temporada 2020-2021. Boletín epidemiológico semanal [Internet]. 2022 Jun [citado 28 Oct 2022]; 30(4):37-44. Disponible en: //revista.isciii.es/index.php/bes/article/view/1229
9. Posadas E, Fisher J. Pediatric bacterial meningitis: an update on early identification and management. Ped Emer Med Pract [Internet]. 2018 Nov [citado 28 Oct 2022]; 15(11):1-20. Disponible en: https://pubmed.ncbi.nlm.nih.gov/30358380/
10. Castañeda Guillot CD, Martínez Martínez R, Castro Sánchez F de J, Castañeda Guillot CD, Martínez Martínez R, Castro Sánchez FJ. La vacunación y sus retos. Dilemas contemporáneos: educación, política y valores [Internet]. 2021 [citado 28 Oct 2022]; 9(Supl.1). Disponible en: http://www.scielo.org.mx/scielo.php?script=sci_abstract&pid=S2007-78902021000800119&lng=es&nrm=iso&tlng=es
11. Sierra-González VG. Vacuna cubana antimeningocócica VA-MENGOC-BC®: Treinta años de uso y potencialidades vigentes. Vaccimonitor [Internet]. 2020 Abr [citado 26 Dic 2022]; 29(1):31-43. Disponible en: http://scieloprueba.sld.cu/scielo.php?script=sci_arttext&pid=S1025-028X2020000100031&lng=es
12. Godoy P, Castilla J, Astray J, Tuells J, Barrabeig I, Domínguez À. La enfermedad meningocócica y las vacunas: algunas respuestas y todavía muchas preguntas. Gac Sanit [Internet]. 2020 Feb [citado 26 Dic 2022]; 34(1):1-3. DOI: https://dx.doi.org/10.1016/j.gaceta.2019.09.004
13. Salgado Balbás Y, Deschamps Perdomo A. Enfermedad meningocócica: a propósito de un caso de exposición ocupacional y análisis de su prevención y control. Rev Asoc Esp Espec Med Trab [Internet]. 2019 [citado 26 Dic 2022]; 28(2):136-143. Disponible en: http://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S1132-62552019000200006&lng=es
